Results 41 to 50 of about 20,556 (211)

Clarithromycin-resistant Helicobacter pylori in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction

open access: yesArquivos de Gastroenterologia, 2010
CONTEXT: Clarithromycin is the most effective drug used in the eradication of infection by Helicobacter pylori. Due to worldwide increase in resistance, pre-treatment susceptibility testing for clarithromycin is recommended.
Ana Kelly Lins   +2 more
doaj   +1 more source

Clinical Resistance of Helicobacter pylori and Its Trend: A 10-year Data Analysis at Peking University People's Hospital

open access: yesXiehe Yixue Zazhi, 2023
Objective  To study the resistance of Helicobacter pylori(Hp) isolated from Peking University People's Hospital to commonly used antibiotics, in order to provide basis for clinical rational drug use.
ZHANG Feifei   +7 more
doaj   +1 more source

Detection of A2142C, A2142G, and A2143G Mutations in 23s rRNA Gene Conferring Resistance to Clarithromycin among Helicobacter pylori Isolates in Kerman, Iran [PDF]

open access: yesIranian Journal of Medical Sciences, 2011
Background: Clarithromycin resistance in Helicbacter pylori has been found to be associated with point mutations in 23s rRNA gene leads to reduced affinity of the antibiotic to its ribosomal target or changing the site of methylation.
Hamid Abdollahi   +4 more
doaj  

Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing [PDF]

open access: yesJournal of Medical Microbiology, 2007
Helicobacter pylori infections can be effectively treated with clarithromycin, a macrolide, in combination with other antibiotics, such as amoxicillin, tetracycline or metronidazole. The failure of H. pylori eradication is mainly associated with macrolide-resistant strains.
Karen-Anja, Moder   +3 more
openaire   +2 more sources

Inaccuracy of routine susceptibility tests for detection of erythromycin resistance of Campylobacter jejuni and Campylobacter coli

open access: yes, 2009
In The Netherlands, both an increase in and regional differences in erythromycin resistance of Campylobacter jejuni and Campylobacter coli have been reported.
Claas, E.C.J.   +19 more
core   +1 more source

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis [PDF]

open access: yesEuropean Respiratory Journal, 2017
Clarithromycin had a good tolerability and safety profile as assessed in MDR-TB patients receiving prolonged treatment http://ow.ly ...
Anne-Fleur Louise Van der Paardt   +14 more
openaire   +3 more sources

Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population [PDF]

open access: yes
Background: In Iran, there is insufficient information on the efficacy of Helicobacter pylori eradication regimens shorter than 10 days. This study aims at assessing the efficacy of 4- and 7-day H. pylori eradication regimens in a high-incidence area of
میکاییلی, جواد   +15 more
core   +1 more source

Clinical Whole Genome Sequencing for Clarithromycin and Amikacin Resistance Prediction and Subspecies Identification of Mycobacterium abscessus. [PDF]

open access: yes, 2021
Mycobacterium abscessus infections are an emerging health care concern in patients with chronic pulmonary diseases, leading to high morbidity and mortality. One major challenge is resistance to clarithromycin, a cornerstone antibiotic with high efficacy.
Mirasol, Ruel   +3 more
core   +1 more source

Susceptibility-Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial. [PDF]

open access: yesMicrobiologyopen
In a randomised trial conducted in a high‐resistance region, PCR‐based susceptibility‐guided therapy showed no superiority over empirical therapy for Helicobacter pylori eradication. Empirical clarithromycin‐containing quadruple therapy remained effective despite high clarithromycin resistance.
Lu K   +11 more
europepmc   +2 more sources

Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma [PDF]

open access: yesAmerican Journal of Hematology, 2014
The combination of clarithromycin, lenalidomide and dexamethasone (BiRd) has led to highly durable responses in newly diagnosed myeloma. However, the ability of clarithromycin to overcome resistance to lenalidomide and dexamethasone (Rd) is not known.
Nilanjan, Ghosh   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy